Heron Therapeutics Inc HRTX:NASDAQ

Last Price$13.55NASDAQ Closing Price as of 4:15PM ET 4/07/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.77(6.03%)
Bid (Size)$12.80 (10)
Ask (Size)$13.60 (4)
Day Low / High$12.82 - 13.59
Volume1.5 M
 

View Biotechnology IndustryPeer Comparison as of 04/07/2020

 

Heron Therapeutics Inc ( NASDAQ )

Price: $13.55
Change: +0.77 (6.03%)
Volume: 1.5 M
4:15PM ET 4/07/2020
 
 

Myriad Genetics Inc ( NASDAQ )

Price: $14.79
Change: -0.53 (3.46%)
Volume: 933.7 K
3:59PM ET 4/07/2020
 
 

Cortexyme Inc ( NASDAQ )

Price: $36.24
Change: -2.56 (6.60%)
Volume: 167.9 K
3:59PM ET 4/07/2020
 
 

Editas Medicine Inc ( NASDAQ )

Price: $21.12
Change: -0.23 (1.08%)
Volume: 1.4 M
4:00PM ET 4/07/2020
 
 

Twist Bioscience Corp ( NASDAQ )

Price: $26.40
Change: -3.33 (11.20%)
Volume: 408.4 K
4:00PM ET 4/07/2020
 

Read more news Recent News

Heron Therapeutics Slips After Posting Worse-Than-Expected Q4 Loss Per Share; Revenue Tops Consensus
2:28PM ET 3/02/2020 MT Newswires

Heron Therapeutics (HRTX) on Monday posted a Q4 net loss of $0.65 per share, compared with a net loss of $0.63 per share a year earlier and wider than the...

Heron Therapeutics Down 4% After FDA Extends Review Period for HTX-011 Non-Opioid Pain Medication
1:57PM ET 2/20/2020 MT Newswires

Heron Therapeutics (HRTX) dropped 4% after the company said the US Food and Drug Administration extended the review period for the company's HTX-011 drug...

Analyst Actions: Needham & Co Cuts Heron Therapeutics Price Target to $48 From $50, Maintains Buy Rating
11:13AM ET 2/20/2020 MT Newswires

Heron Therapeutics' (HRTX) average rating among analysts is a buy, with an average price target of $47. Price: 20.21, Change: -1.45, Percent Change: -6.69...

Heron Therapeutics Says Drug for Postoperative Pain Receives Priority Review Status From Health Canada
9:11AM ET 12/03/2019 MT Newswires

Heron Therapeutics (HRTX) said Tuesday that Health Canada has accepted and granted a Priority Review Status for HTX-011, which is intended for the...

Company Profile

Business DescriptionHeron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA. View company web site for more details
Address4242 Campus Point Court
San Diego, California 92121
Phone+1.858.251.4400
Number of Employees198
Recent SEC Filing03/02/202010-K
President, Chief Executive Officer & DirectorBarry D. Quart
Chief Financial Officer & Senior VP-FinanceRobert E. Hoffman
Chief Scientific Officer & SVP-PharmaceuticalThomas B. Ottoboni
Chief Medical OfficerChris M. Storgard

Company Highlights

Price Open$13.41
Previous Close$12.78
52 Week Range$9.60 - 26.81
Market Capitalization$1.2 B
Shares Outstanding90.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement05/14/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.51
Beta vs. S&P 500N/A
Revenue$77.5 M
Net Profit Margin-140.27%
Return on Equity-61.74%

Analyst Ratings as of 03/02/2020

Buy
9
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset